Your session is about to expire
← Back to Search
Oxazolidinone Antibiotic
Linezolid vs Penicillin for Syphilis
Phase 2
Recruiting
Led By Jeffrey D Klausner, MD MPH
Research Sponsored by University of Southern California
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing linezolid, an antibiotic taken by mouth, to treat syphilis. It includes people with and without HIV. Linezolid works by stopping bacteria from growing. The study aims to find an alternative to penicillin, especially for those who can't use it due to allergies or shortages.
Who is the study for?
This trial is for individuals aged 16 or older diagnosed with primary, secondary, or early latent syphilis and have a recent RPR titer of at least 1:8. People living with HIV can join if they're on treatment and meet certain viral load or CD4 count criteria. Pregnant individuals, those on specific antibiotics or psychotropic meds, and anyone allergic to the study drugs cannot participate.
What is being tested?
The study compares the effectiveness of two treatments for syphilis: Group A receives Penicillin (the standard treatment), while Group B gets Linezolid for 10 days. The goal is to see if Linezolid is an effective alternative.
What are the potential side effects?
Linezolid may cause headaches, nausea, diarrhea, vomiting; it might also affect blood counts leading to anemia or decrease in white cells increasing infection risk. Penicillin side effects include allergic reactions ranging from rashes to more severe responses.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Response to Treatment
Secondary study objectives
Globus Pallidus
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Linezolid 10 DayExperimental Treatment1 Intervention
Oral linezolid 600mg, taken twice a day for 10 days
Group II: Benzathine Penicillin GActive Control1 Intervention
Single intramuscular injection of 2.4 million units of benzathine penicillin G
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatment for Syphilis is Penicillin, which works by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. Linezolid, a treatment under study, inhibits bacterial protein synthesis by binding to the bacterial ribosome and preventing the formation of a functional 70S initiation complex.
These mechanisms are important for Syphilis patients as they ensure the effective elimination of the bacteria, reducing symptoms and preventing further complications.
Therapy for nonvenereal treponematoses: review of the efficacy of penicillin and consideration of alternatives.
Therapy for nonvenereal treponematoses: review of the efficacy of penicillin and consideration of alternatives.
Find a Location
Who is running the clinical trial?
University of Southern CaliforniaLead Sponsor
944 Previous Clinical Trials
1,604,621 Total Patients Enrolled
1 Trials studying Syphilis
400 Patients Enrolled for Syphilis
Universidad Peruana Cayetano HerediaOTHER
79 Previous Clinical Trials
62,304 Total Patients Enrolled
1 Trials studying Syphilis
400 Patients Enrolled for Syphilis
The University of Texas Health Science Center, HoustonOTHER
949 Previous Clinical Trials
345,001 Total Patients Enrolled
2 Trials studying Syphilis
2,424 Patients Enrolled for Syphilis
Share this study with friends
Copy Link
Messenger